Effect of Prucalopride in the Treatment of Chronic Constipation in Asian and Non-Asian Women: A Pooled Analysis of 4 Randomized, Placebo-controlled Studies
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND/AIMS: To compare the efficacy and safety of prucalopride, a novel selective high-affinity 5-hydroxytryptamine type 4 receptor agonist, versus placebo, in Asian and non-Asian women with chronic constipation (CC). METHODS: Data of patients with CC, receiving once-daily prucalopride 2-mg or placebo for 12-weeks, were pooled from 4 double-blind, randomized, phase-III trials (NCT00488137, NCT00483886, NCT00485940 and NCT01116206). The efficacy endpoints were: average of ≥ 3 spontaneous complete bowel movements (SCBMs)/week; average increases of ≥ 1 SCBMs/week; and change from baseline in each CC-associated symptom scores (bloating, abdominal pain, hard stool and straining). RESULTS: Overall, 1,596 women (Asian [26.6%], non-Asian [73.4%]) were included in this analysis. Significantly more patients in the prucalopride group versus placebo experienced an average of ≥ 3 SCBMs/week in Asian (34% vs. 11%, P < 0.001) and non-Asian (24.6% vs. 10.6%, P < 0.001) subgroups. The number of patients reporting an increase of≥ 1 SCBMs/week from baseline was significantly higher in the prucalopride group versus placebo among both Asian (57.4% vs. 28.3%, P < 0.001) and non-Asian (45.3% vs. 24.0%, P < 0.001) subgroups. The difference between the subgroups was not statistically significant. Prucalopride significantly reduced the symptom scores for bloating, hard stool, and straining in both subgroups. CONCLUSIONS: Prucalopride 2-mg once-daily treatment over 12-weeks was more efficacious than placebo in promoting SCBMs and improve-ment of CC-associated symptoms in Asian and non-Asian women, and was found to be safe and well-tolerated. There were numeric differences between Asian and non-Asian patients on efficacy and treatment emergent adverse events, which may be partially due to the overlap with functional gastrointestinal disorders in non-Asian patients.(J Neurogastroenterol Motil 2014;20:458-468).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic constipation: a survey of the patient perspective
JOHANSON, J. F., & KRALSTEIN, J. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03238.x · Cited by 617 · cited 3×
“Chronic constipation (CC) is a common disorder with prevalence rates reported between 2% to 27% in the general population.(1,2) In developed countries, prevalence estimates range from 10% to 15%.”
A placebo-controlled trial of prucalopride for severe chronic constipation
Camilleri, M., Kerstens, R., Rykx, A., & Vandeplassche, L. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800670 · Cited by 576 · cited 3×
“Most importantly, prucalopride has been shown to be effective and well-tolerated in the treatment of CC in a number of randomized controlled clinical trials and follow-up studies lasting as long as 18 months.(9,15,17,18) Prucalopride is approved in many countries for the symptomatic treatment of CC in women, in whom l…”
QUIGLEY, E. M. M., VANDEPLASSCHE, L., KERSTENS, R., & AUSMA, J. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03884.x · Cited by 344
Self-citationTack, J., Camilleri, M., Chang, L., Chey, W. D., Galligan, J. J., Lacy, B. E., Müller‐Lissner, S., Quigley, E. M. M., Schuurkes, J., De Maeyer, J. H., et al. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05011.x · Cited by 286
Self-citationKe, M., Zou, D., Yuan, Y., Li, Y., Lin, L., Hao, J., Hou, X., & Kim, H. J. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2012.01983.x · Cited by 107 · cited 2×
“clinically relevant, as accepted in the 3 pivotal studies and the Asia-Pacific study.(9,17,18,20) Although, there was no head-to-head statistical comparison”
MethodSelf-citation
Cited by
Sajid, M. S., Hebbar, M., Baig, M. K., Li, A., & Philipose, Z. (2016) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm16004 · Cited by 65
“When reported, the incidence of serious adverse events was statistically similar for placebo and prucalopride groups.(45,46,54,57,63,65) Like other 5-HT4 agonists such as cisapride, there were concerns about the risk of cardiac side effects after the use of prucalopride because prucalopride has not been found to inter…”
BackgroundResultClinical practice guidelines for irritable bowel syndrome in Korea, 2017 revised edition
Song, K. H., Jung, H.-K., Kim, H. J., Koo, H. S., Kwon, Y. H., Shin, H. D., Lim, H. C., Shin, J. E., Kim, S. E., Cho, D. H., et al. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm17145 · Cited by 47
(2009) · doi:10.4166/kjg.2019.73.2.84 · Cited by 11
Self-citation
Metadata
- Authors
- Ke, M., Tack, J., Quigley, E. M. M., Zou, D., Choi, S. C., Leelakusolvong, S., Liu, A., & Kim, J.
- Venue
- Journal of Neurogastroenterology and Motility
- Published
- 2014-10-30
- Volume
- 20
- Issue
- 4
- Pages
- 458-468
- ISSN
- 2093-0879 (ISSN-L)
- 2093-0887
- OpenAlex
- W1970585703
- Cited by
- 25
- References
- 5
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Prucalopride in the Treatment of Chronic Constipation in Asian and Non-Asian Women: A Pooled Analysis of 4 Randomized, Placebo-controlled Studies. https://app.cochat.ai/papers/10.5056/jnm.20.458
- The paper
- Ke, M., Tack, J., Quigley, E. M. M., Zou, D., Choi, S. C., Leelakusolvong, S., Liu, A., & Kim, J. (2014). Effect of Prucalopride in the Treatment of Chronic Constipation in Asian and Non-Asian Women: A Pooled Analysis of 4 Randomized, Placebo-controlled Studies. Journal of Neurogastroenterology and Motility. https://doi.org/10.5056/jnm.20.458
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.